文献速递冠心病血脂与心血管预防

既往心肌梗死且未行冠脉支架患者的长期替格瑞洛二级预防:PEGASUS-TIMI 54 分析

Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.
PubMed 文献 · Eur Heart J · 2020-01-01

结果显示,无支架史患者安慰剂组 MACE 风险更高(13.2% vs 8.0%,校正 HR 1.41,95%CI 1.15-1.73),替格瑞洛(合并剂量)降低 MACE 的相对风险在无支架史(HR 0.82,95%CI 0.68-0.99)与有支架史(HR 0.85,95%CI 0.75-0.96)患者中相似(交互 P=0.76)。结论:长期替格瑞洛减少既往 MI 患者血栓事件,无论是否曾行冠脉支架。

要点

  • 无冠脉支架史的既往 MI 患者基线 MACE 风险更高(13.2% vs 8.0%)。
  • 替格瑞洛降低 MACE 的相对风险在无支架史与有支架史患者中相似。
  • 高危既往 MI 患者即使未行支架,也可考虑长期替格瑞洛。

核心结论

  • 长期替格瑞洛降低既往 MI 患者血栓事件,无论是否曾行冠脉支架。
  • 数据支持 DAPT 在预防自发性动脉粥样硬化血栓事件中的获益。
  • 高危既往 MI 患者即使未接受支架治疗,也可考虑长期替格瑞洛。

研究设计与样本

  • PEGASUS-TIMI 54 的预指定分析,随机对照试验。
  • 患者接受替格瑞洛 60 mg、90 mg 或安慰剂每日两次,均加用阿司匹林。
  • 基线无冠脉支架史者共 4199 例。

主要发现

  • 无冠脉支架史患者安慰剂组 MACE 风险更高(13.2% vs 8.0%,校正 HR 1.41,95%CI 1.15-1.73)。
  • 替格瑞洛(合并剂量)降低 MACE 的相对风险在无支架史患者中 HR 0.82(95%CI 0.68-0.99)。
  • 有支架史患者中替格瑞洛降低 MACE 的 HR 0.85(95%CI 0.75-0.96),交互 P=0.76。

关键数值与推荐

  • 主要疗效终点 MACE 为心血管死亡、MI 或卒中的复合终点。
  • 无冠脉支架史定义为基线无冠脉支架史。
  • 替格瑞洛剂量为 60 mg 或 90 mg 每日两次。

临床怎么用

  • 对既往 MI 且伴高危特征的患者,评估长期替格瑞洛时应考虑其是否曾行冠脉支架。
  • 无冠脉支架史的高危既往 MI 患者也可从长期替格瑞洛联合阿司匹林中获益。

局限性

  • 本研究为预指定分析,非独立试验。
  • 无冠脉支架史亚组样本量相对较小(4199 例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients with prior myocardial infarction (MI). While much of the discussion around prolonged DAPT has been focused on stented patients, patients with prior MI without prior coronary stenting comprise a clinically important subgroup. METHODS AND RESULTS: This was a pre-specified analysis from PEGASUS-TIMI 54, which randomized 21 162 patients with prior MI (1-3 years) and additional high-risk features to ticagrelor 60 mg, 90 mg, or placebo twice daily in addition to aspirin. A total of 4199 patients had no history of coronary stenting at baseline. The primary efficacy outcome (MACE) was the composite of cardiovascular death, MI, or stroke. Patients without history of coronary stenting had higher baseline risk of MACE [13.2% vs. 8.0%, adjusted hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.15-1.73, in the placebo arm]. The relative risk reduction in MACE with ticagrelor (pooled doses) was similar in patients without (HR 0.82, 95% CI 0.68-0.99) and with prior stenting (HR 0.85, 95% CI 0.75-0.96; P for interaction = 0.76). CONCLUSION: Long-term ticagrelor reduces thrombotic events in patients with prior MI regardless of whether they had prior coronary stenting. These data highlight the benefits of DAPT in prevention of spontaneous atherothrombotic events and indicate that long-term ticagrelor may be considered in high-risk patients with prior MI even if they have not been treated with stenting. CLINICALTRIALS.GOV IDENTIFIER: NCT01225562.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Furtado RHM, Nicolau JC, Magnani G, et al. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. Eur Heart J. 2020. PMID: 31811715. doi:10.1093/eurheartj/ehz821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。